<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Pfizer (PFE) Reports Positive Phase 3 Results For COVID-19 Vaccine In Adults — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Pfizer (PFE) Reports Positive Phase 3 Results For COVID-19 Vaccine In Adults</h2>
    <div class="badge">2025-09-08T17:22:30+00:00</div>
    <ul>
      <li>This news coincided with a quarter in which Pfizer&#x27;s share price rose by 2.39%.</li>
<li>Over the past year, Pfizer&#x27;s total shareholder return, including dividends, experienced a 9.47% decline.</li>
<li>You should learn about the 2 risks we&#x27;ve spotted with Pfizer.</li>
<li>Despite the current upward share price movement, Pfizer&#x27;s share price of US$24.88 remains below the consensus price target of US$28.86, indicating a perceived discount to its estimated fair value potential.</li>
<li>While the vaccine advancements could potentially boost revenues, such increases might be overshadowed by anticipated declines due to the loss of exclusivity on key drugs like Eliquis and Ibrance, expected by 2027.</li>
<li>This article by Simply Wall St is general in nature.</li>
<li>Simply Wall St has no position in any stocks mentioned.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Pfizer (PFE) Reports Positive Phase 3 Results For COVID-19 Vaccine In Adults\n• This news coincided with a quarter in which Pfizer&#x27;s share price rose by 2.39%.\n• Over the past year, Pfizer&#x27;s total shareholder return, including dividends, experienced a 9.47% decline.\n• You should learn about the 2 risks we&#x27;ve spotted with Pfizer.\n• Despite the current upward share price movement, Pfizer&#x27;s share price of US$24.88 remains below the consensus price target of US$28.86, indicating a perceived discount to its estimated fair value potential.\n• While the vaccine advancements could potentially boost revenues, such increases might be overshadowed by anticipated declines due to the loss of exclusivity on key drugs like Eliquis and Ibrance, expected by 2027.\n• This article by Simply Wall St is general in nature.\n• Simply Wall St has no position in any stocks mentioned." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/pfizer-pfe-reports-positive-phase-172230928.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>